Prognostic Implications of Evolving Universal Definitions of Periprocedural Myocardial Infarction in Patients With Acute Coronary Syndrome

S Sergio Leonardi (University of Pavia and Fondazione IRCCS Policlinico San Matteo, Italy (S.L.).) A Antonio Landi (Cardiocentro Ticino Institute, Ente Ospedaliero Cantonale (EOC), Lugano, Switzerland (A.L.).) A Andrea Zito (Fondazione Poliambulanza Istituto Ospedaliero, Brescia, Italy (A.Z.).) M Mattia Branca (Department of Clinical Research, University of Bern, Switzerland (M.B., D.H.).) E Enrico Frigoli (Division of Cardiology, Cardiocentro Ticino Institute, Ente Ospedaliero Cantonale, Lugano, Switzerland (A.L., E.F., A.M., M.V.).) G Giuseppe Ando’ (Azienda Ospedaliera Universitaria Policlinico “Gaetano Martino,” University of Messina, Italy (G.A.).) C Carlo Briguori (Mediterranea Cardiocentro, Naples, Italy (C.B.).) P Paolo Calabrò A Andrea Gagnor (Cardiology Department, Maria Vittoria Hospital, Turin, Italy (A.G.).) R Roberto Garbo (Maria Pia Hospital, GVM Care & Research, Turin, Italy (R.G.).) D Dik Heg U Ugo Limbruno (Cardiology Department, Misericordia Hospital, Grosseto, Italy (U.L.).) A Andrea Milzi (Division of Cardiology, Cardiocentro Ticino Institute, Ente Ospedaliero Cantonale, Lugano, Switzerland (A.L., E.F., A.M., M.V.).) E Elmir Omerovic F Filippo Russo (Interventional Cardiology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy (F.R.).) M Manel Sabaté (Cardiology Department, Cardiovascular Institute, Hospital Clinic, Institut d’Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Centro de Investigación Biomédica en Red Enfermedades Cardiovaculares (CIBER-CV), Barcelona) A Andrea Santarelli (Cardiology Unit, Bufalini Hospital, Cesena, Italy (A.S.).) G Gennaro Sardella (Department of Cardiology, Policlinico Umberto I, Sapienza University of Rome, Rome) P Paolo Tosi (IRCCS Ospedale Sacro Cuore Don Calabria, Negrar, Verona, Italy (P.T.).) A Arnoud W.J. Van’t Hof (Cardiovascular Research Institute Maastricht, Maastricht University, the Netherlands (A.W.J.V.H.)) P Pascal Vranckx (Department of Cardiology and Critical Care Medicine, Hartcentrum Hasselt, Jessa Ziekenhuis, Belgium (P.V.).) M Marco Valgimigli (Cardiocentro Ticino Institute, Ente Ospedaliero Cantonale, Università della Svizzera Italiana, Lugano, Switzerland)

Abstract

BACKGROUND: The universal definition of percutaneous coronary intervention (PCI)–related myocardial infarction (MI) has been substantially updated over the years, including an increase in the biomarker threshold (from 3 to 5 times the upper reference limit) and the introduction of ancillary criteria such as ischemic symptoms and electrocardiographic or angiographic complication. The impact of these changes in patients with acute coronary syndrome (ACS) remains incompletely understood. The objective of this study was to compare prognostic implications of evolving universal definitions of PCI-MI in a large cohort of patients with ACS from the MATRIX trial (Minimizing Adverse Haemorrhagic Events by Transradial Access Site and Systemic Implementation of AngioX). METHODS: Among 6724 patients undergoing PCI in the MATRIX trial, PCI-MI was prospectively adjudicated by the second, third and fourth universal definition of MI (UDMI). The 2 co-primary end points were all-cause and cardiovascular death (from 24 hours to 1 year after PCI) in patients with non–ST-segment–elevation ACS. Hazard ratios and 95% CIs were generated for primary and secondary end points with the use of Cox proportional hazards time-to-event analyses for each MI definition. RESULTS: PCI-MI occurred in 590 patients (9%) with the second UDMI, 193 (3%) with the third UDMI, and 182 (3%) with the fourth UDMI applied in the overall ACS population. Among patients with non–ST-segment–elevation ACS, the corresponding figures were 15%, 5%, and 5%. Only PCI-MI defined by the fourth UDMI in patients with non–ST-segment–elevation ACS was associated with increased risks of all-cause (hazard ratio, 2.08 [95% CI, 1.00–4.30]; P =0.048) and cardiovascular (hazard ratio, 2.62 [95% CI, 1.03–6.65]; P =0.043) death. In patients with ST-segment–elevation myocardial infarction, PCI-MI was uncommon (1% to 4% depending on the working definition) and was not associated with increased mortality. In the absence of objective ancillary criteria (electrocardiographic and angiographic complications), isolated troponin elevations up to 20 times the upper reference limit were not associated with increased mortality risk. CONCLUSIONS: PCI-MI defined according to the fourth UDMI was associated with increased risks of 1-year mortality only in patients with non–ST-segment–elevation ACS. These data support the evolution of the universal definition of PCI-MI. REGISTRATION: URL: http://www.clinicaltrials.gov ; Unique identifier: NCT01433627.

Article Details

Journal Circulation
Volume / Issue Vol. 153, Issue 4
Published January 27, 2026
Pages 230-242
ISSN 0009-7322
Publisher Lippincott Williams & Wilkins

Journal Info

Circulation

Lippincott Williams & Wilkins

ISSN: 0009-7322 Health Sciences

Authors (22)

S

Sergio Leonardi

University of Pavia and Fondazione IRCCS Policlinico San Matteo, Italy (S.L.).

A

Antonio Landi

Cardiocentro Ticino Institute, Ente Ospedaliero Cantonale (EOC), Lugano, Switzerland (A.L.).

A

Andrea Zito

Fondazione Poliambulanza Istituto Ospedaliero, Brescia, Italy (A.Z.).

M

Mattia Branca

Department of Clinical Research, University of Bern, Switzerland (M.B., D.H.).

E

Enrico Frigoli

Division of Cardiology, Cardiocentro Ticino Institute, Ente Ospedaliero Cantonale, Lugano, Switzerland (A.L., E.F., A.M., M.V.).

G

Giuseppe Ando’

Azienda Ospedaliera Universitaria Policlinico “Gaetano Martino,” University of Messina, Italy (G.A.).

C

Carlo Briguori

Mediterranea Cardiocentro, Naples, Italy (C.B.).

P

Paolo Calabrò

A

Andrea Gagnor

Cardiology Department, Maria Vittoria Hospital, Turin, Italy (A.G.).

R

Roberto Garbo

Maria Pia Hospital, GVM Care & Research, Turin, Italy (R.G.).

D

Dik Heg

U

Ugo Limbruno

Cardiology Department, Misericordia Hospital, Grosseto, Italy (U.L.).

A

Andrea Milzi

Division of Cardiology, Cardiocentro Ticino Institute, Ente Ospedaliero Cantonale, Lugano, Switzerland (A.L., E.F., A.M., M.V.).

E

Elmir Omerovic

F

Filippo Russo

Interventional Cardiology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy (F.R.).

M

Manel Sabaté

Cardiology Department, Cardiovascular Institute, Hospital Clinic, Institut d’Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Centro de Investigación Biomédica en Red Enfermedades Cardiovaculares (CIBER-CV), Barcelona

A

Andrea Santarelli

Cardiology Unit, Bufalini Hospital, Cesena, Italy (A.S.).

G

Gennaro Sardella

Department of Cardiology, Policlinico Umberto I, Sapienza University of Rome, Rome

P

Paolo Tosi

IRCCS Ospedale Sacro Cuore Don Calabria, Negrar, Verona, Italy (P.T.).

A

Arnoud W.J. Van’t Hof

Cardiovascular Research Institute Maastricht, Maastricht University, the Netherlands (A.W.J.V.H.)

P

Pascal Vranckx

Department of Cardiology and Critical Care Medicine, Hartcentrum Hasselt, Jessa Ziekenhuis, Belgium (P.V.).

M

Marco Valgimigli

Cardiocentro Ticino Institute, Ente Ospedaliero Cantonale, Università della Svizzera Italiana, Lugano, Switzerland